2 healthcare stocks to buy amid monkeypox and COVID-19: DOC & WELL

3 min read | June 30, 2022 03:08 AM PDT | By Raza Naqvi

Highlights

  • The healthcare index has declined 46.8 per cent year-to-date (YTD).
  • There were 276 instances of monkeypox in Canada as of Wednesday.
  • The monkeypox disease can spread from animals to people.

New, highly contagious Omicron subvariants are reportedly causing the spike in COVID-19 cases in Quebec. The Director of Public Health in Quebec, Dr Luc Boileau, reportedly said that despite the surge, it's too soon to think about reintroducing public health restrictions.

Meanwhile, the National Advisory Committee on Immunization (NACI) said that regardless of how many booster shots they have already had, people at high risk of developing serious illness from COVID-19 infection should be offered a booster injection this fall.

Apart from the coronavirus cases, Canada is witnessing a spiked in monkeypox cases. The Public Health Agency of Canada (PHAC) revealed that there were 276 instances of monkeypox in Canada as of Wednesday. British Columbia has four cases, Alberta has five, Ontario has 67, and Quebec has 202.

According to PHAC, it is conducting diagnostic tests for the monkeypox virus. As per the World Health Organization (WHO), the monkeypox disease can spread from animals to people, and the same family of viruses causes it as smallpox, which was deemed extinct in 1980.

In Canada, the healthcare sector has dipped significantly in 2022. The healthcare index has declined 46.8 per cent year-to-date (YTD).

You could consider buying a few healthcare stocks on the dip if you are a long-term investor. Let's look at them:

CloudMD Software & Services Inc. (TSXV:DOC)

With the help of primary care clinics, telemedicine, and artificial intelligence, CloudMD, is a software-as-a-service (SaaS) healthcare startup. The company provides technology solutions to medical clinics all across the nation.

In the first quarter, CloudMD's revenue was C$ 41.4 million, up from C$ 8.8 million in Q1 2021. Despite the decline in the stock price, CloudMD's financials are better than the previous year's first quarter.

CloudMD reduced its net loss to C$ 5.6 million compared to a net loss of C$ 15.1 million in Q4 2021. On June 29, the price of the DOC stock was C$ 0.403 per share.

In Q1 2022, the healthcare company claimed that it is on track to achieve profitability in future. However, investors will have to wait for the next quarter's results to see if the company is on track.


©2022 Kalkine Media® 

WELL Health Technologies Corp. (TSX:WELL)

In British Columbia, the firm owns the largest single chain of care clinics. They also offer Emergency Medical Records (EMR) services to many medical facilities.             

WELL achieved record quarterly revenues in the first quarter as it jumped by 395 per cent year-over-year (YoY) to C$ 126.5 million. Meanwhile, the adjusted net income was C$ 8.6 million compared to a loss of C$ 2.4 million in Q1 2021.

Notably, the company's virtual services revenues climbed 174 per cent YoY, and as the world has moved online, the company could further expand its virtual services.

The company is also expanding its presence by making acquisitions and focusing on improving the services of its subsidiaries.

Please note, the above content constitutes a very preliminary observation or view based on digital trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next